• 1
  • Platform
One-stop drug design service
To provide the highest quality drug research and development design, MoMed has launched a multi-dimensional intelligent technology platform, providing comprehensive one-stop service. MoMed Biotech platform adopts cutting-edge technology, covering the entire process of drug design, and can efficiently and quickly customize solutions according to your personalized and unique needs.
High-performance research platform of target protein working mechanism

The Nobel Prize-winning computational biology method is suitable for the study of ultra-large-scale biomolecular systems.

0 1- High-performance research platform of target protein working mechanism

Multi-standard tandem screening completes the virtual screening of a billion-scale drug small molecule library.

0 2- High-throughput platform of drug molecule virtual screening

The world 's cutting-edge generative artificial intelligence model meets the research and development needs of small molecules, macromolecules, antibody-coupled drugs, PROTAC and other types of drugs.

0 3- High-intelligent platform of artificial intelligence drug design

The intelligent contribution of professional drug research and development scientists " Design-Experiment-Optimization " cyclic iterative optimization.

0 4- High-level optimization platform of drug molecular design

Self-owned intellectual property rights of the drug molecular fragment database AI-supported patchwork drug fragment assembly scheme.

0 5- High-scale drug molecular fragment database platform

Significantly increase the rate of development of innovative drugs to support the parallel development of multiple pipelines.

0 6- High-efficiency multi-pipeline drug R&D platform

  • 2
  • Service
The expert team perfectly covers the technical process and provides technical support for each step
To provide the highest quality drug research and development design, MoMed has launched a multi-dimensional intelligent technology platform, providing comprehensive one-stop service. MoMed Biotech platform adopts cutting-edge technology, covering the entire process of drug design, and can efficiently and quickly customize solutions according to your personalized and unique needs.
  • 3
  • News
News Center
Momed News | Momed Biotech Technology Embarks on a New Journey with Joyful Relocation

Momed Biotech (Hangzhou) Biotechnology Co., Ltd., a process spanning nearly five months, saw the completion of its over 1000m2 office renovation project, which commenced in December 2022. In April 2023, much anticipated by many, Chenzhu Technology officially relocated to 60 Hongfeng Road, Linping District, Hangzhou.

2023-04-18
The Bai Chen Research Group Publishes Paper in the Biology Journal: "The Nature of Functional Features of Different Classes of G-Protein-Coupled Receptors"

The Bai Chen Research Group Publishes Paper in the Biology Journal: "Explaining the Structure-Function Relationship of Three Types of G-Protein-Coupled Receptors from an Energetic Perspective"

2022-12-20
The Bai Chen Research Group Publishes Paper in the International Journal of Molecular Sciences

"In recent years, traditional drug design has required extensive research time and development costs. Computational methods have been widely used to enhance the efficacy and effectiveness of drug discovery and pipelines, leading to the approval of numerous new drugs. The White Morning Research Group published a review article in the International Journal of Molecular Sciences, focusing on the application and challenges of computational methods in assisting drug target identification, lead compound discovery, and optimization."

2022-11-05
Interview with ' China High-tech ' Magazine by Prof. Bai Chen

In August 2022, Professor Bai Chen was interviewed by ' China High-tech ' magazine. He described his experience in the field of macromolecular mechanism research of drug targets and his vision and goals for the future of the biomedical industry. The relevant report is published in the ' China High-tech ' magazine in August 2022.

2022-10-07
The Bai Chen Professor's Research Group Publishes Paper in Aims Microbiology Investigating the Immune Evasion Capabilities of Various Variants of the Novel Coronavirus.

The emergence of variants of the SARS-CoV-2 virus poses challenges to the effectiveness of currently available vaccines and therapeutic antibodies. The research group led by Professor Bai Chen has analyzed the impact of mutations on the binding affinity between the spike protein of the novel coronavirus and neutralizing antibodies, antibodies from recovered patients, and artificially designed antibody mimetics by calculating changes in binding free energy. The study evaluates the differences between target sites on the spike protein for several antibodies. The results provided in this paper ma

2022-09-29
Professor BAI Chen participated in the 2022 Sixth World Growth Conference ' Innovating Linping Wisdom Hongfeng '.

On June 28, Professor Bai Chen was invited to participate in the " Innovation Linping Wisdom Hongfeng " High-efficiency Achievement Transformation and Innovation Summit Forum at the Linping venue of the Sixth World Growth Conference in Hangzhou. This forum is guided by the China Association for Science and Technology, sponsored by the Hangzhou Municipal People 's Government, the Zhejiang Provincial Committee of the People 's Republic of China, and the China Investment Development Promotion Association. It is undertaken by the people 's government of Linping District, Linping National Economic

2022-06-28
  • 4
  • Partner
Partners